A Phase 2 interventional study of Reparixin continuous infusion and reparixin intermittent infusion in Ischemia-Reperfusion Injury and Kidney Diseases, sponsored by Dompé Farmaceutici S.p.A. Completed at 9 sites in 4 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-01-10.
Sponsored by Dompé Farmaceutici S.p.A · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Reperfusion Injury with a site in Italy — 4 open to participants now, 4 under way, none of them phase 3. Reperfusion Injury · Italy.
Among the 11 studies in Reperfusion Injury with a site in Italy, this one is the 5th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2005, is one of 2 in phase 2, and was the 1st registered.
260 studies on the registry are indexed under Reperfusion Injury; 43 are open to participants now.
Browse Reperfusion Injury studies →4 of the 11 studies in Reperfusion Injury with a site in Italy are open now. Recruiting first, the newest first:
The Mediterranean Institute for Transplantation and Advanced Specialized Therapies · Sites in Italy
Ages 18+
Azienda Ospedaliero-Universitaria di Modena · Sites in Italy
Ages 18+
Papa Giovanni XXIII Hospital · Sites in Italy
Ages 18–70
The Mediterranean Institute for Transplantation and Advanced Specialized Therapies · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 28 Reperfusion Injury studies recruiting now, 16 (57%) set no upper age limit and 7 (25%) stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 80 is above the median of 60 across 212 interventional studies indexed under Reperfusion Injury.
Median enrollment 60 across the 10 interventional studies, 213 across the 1 observational. Of the 5 that completed or were terminated, 1 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 11 have an industry lead sponsor. The 10 most frequent:
Dompé Farmaceutici S.p.A is the lead sponsor of 52 studies on the registry; 4 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 18 (100%) have results posted.
Dompé Farmaceutici S.p.A has 3 studies filed under Reperfusion Injury — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Reperfusion Injury with a site in Italy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The chemokine CXCL8 plays a key role in the recruitment and activation of polymorphonuclear neutrophils in post-ischemia reperfusion injury after solid organ transplantation. Reparixin is a novel, specific inhibitor of CXCL8. This study is configured to explore the safety and efficacy of reparixin in preventing the delayed graft function (DGF) after kidney transplantation.
Delayed graft function (DGF) is the most common allograft complication in the immediate kidney post-transplant period, affecting 25-35% of all patients who receive a cadaver graft, but rates up to 50% have been reported, especially in recipients of kidneys from marginal donors. It is an important clinical complication as it requires dialysis, prolongs hospitalisation, raises the cost of transplantation, and makes more difficult the management of immunosuppressive therapy. Although the effects of DGF on long-term graft function are still debated, there is overall increasing evidence that DGF reduces long-term graft survival. Moreover, given the well documented impact of acute rejection on long-term graft survival, it is conceivable that DGF and acute rejection synergize in negatively influencing long-term graft survival. Kidney reperfusion, after long cold ischemia period, is associated with an inflammatory reaction characterized by massive polymorphonuclear leukocyte (PMN) infiltration both at the glomerular and tubular levels. The importance of CXCL8 in recruiting PMN in kidney tissue during the ischemic time and after reperfusion has been clearly documented.
The efficacy of reparixin in preventing PMN infiltration and tissue damage in rat models of kidney transplantation and lung transplantation, as well as the safety shown in human phase 1 studies, provide the rationale for a clinical study aimed at evaluating the effect of reparixin in preventing DGF after kidney transplantation
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Continuous iv infusion into a (high flow) central vein (or through an arterio-venous fistula) by an infusion pump. A dose of 2.772 mg/kg/h was administered for12 hours.
Drug: Reparixin continuous infusion
Intermittent iv infusion into a (high flow) central vein (or through an arterio-venous fistula) by an infusion pump. A dose of 2.244 mg/kg was administered over a 30-minute period, followed by a 1.5-hour interval. Twelve doses were administered over a total period of 22.5 hours.
Drug: reparixin intermittent infusion
Continuous/intermittent iv infusion of a volume/schedule matched saline into a (high flow) central vein (or through an arterio-venous fistula) by an infusion pump.
Other: placebo infusion
The Investigational Product was administered as an intravenous infusion into a (high flow) central vein or through an arterio-venous fistula, by an infusion pump adequate to provide reliable infusion rates, as per treatment schedule. Total infusion volume did not exceed 500 mL/24 hours. A dose of 2.772 mg/kg body weight/hour was to be administered for 12 hours. Placebo was volume/schedule matched saline.
Also known as: REP
A dose of 2.244 mg/kg body weight was to be administered over a 30-minute period, followed by a 1.5-hour interval. Twelve doses were to be administered over a total period of 22.5 hours. Placebo was volume/schedule matched saline.
Also known as: REP
placebo was volume/schedule matched saline
Creatinine Clearance (CrCl) in the Immediate Post-transplant Period
CrCl was determined by two 60 minute urine collections, during the time intervals 1-3 and 10-12 hours of allograft reperfusion. Blood was withdrawn at the midpoint of each urine collection. CrCl at each timepoint was calculated according to the formula: creatinine clearance (mL/minutes) = urine creatinine (mmol/L) x urine volume (mL) / serum creatinine (mmol/L) x time of collection (minutes) An average was to be calculated from the two 60 minute values in each interval.
Time frame: 1-3 and 10-12 hours post allograft reperfusion
Renal Function Tests - Serum Creatinine
Serum creatinine (SrCr) was measured daily from Day 1 up to 7 days post-transplant or up to hospital discharge, whichever occurred earlier; in patients undergoing dialysis, SrCr values were measured immediately before dialysis.
Time frame: daily up to day 7 post-transplant or hospital discharge
Renal Function Tests - Calculated Glomerular Filtration Rate
Calculated glomerular filtration rate (GFR) was measured daily from Day 1 up to 7 days post-transplant or up to hospital discharge, whichever occurred earlier; in patients undergoing dialysis, SrCr values were measured immediately before dialysis
Time frame: from Day 1 up to 7 days post-transplant or up to hospital discharge
Renal Function Tests - Urine Output
Urine output, measured in the interval from transplant to 8:00 of Day 1, and then daily from Day 2 up to 7 days post-transplant or up to hospital discharge, whichever occurred earlier
Time frame: from Day 1 up to 7 days post-transplant or up to hospital discharge
Number of Patients Requiring Dialysis Within 7 Days Post-transplant
The number of patients who required dialysis within 7 days post-transplant was evaluated.
Time frame: up to day 7 post-transplant
Number of Days on Dialysis Before Resuming Kidney Function
the number of days on dialysis before resuming kidney function was evaluated.
Time frame: up to Day 7 post-transplant
Number of Patients With Immediate, Slow and Delayed Graft Function
The number of patients who required dialysis within 7 days post-transplant was evaluated. Immediate graft function: SrCr ≤3 mg/dL on post operative day 5) Slow graft function: SrCr \>3 mg/dL dL on post operative day 5, no need of dialysis) Delayed graft function: Dialysis needed in the first week)
Time frame: day 5 post-transplant
Duration of Hospital Stay
The mean duration of hospital stay was evaluated.
Time frame: first 30 days post-transplant
Mortality
Mortality in the first 30 days post-transplant was evaluated.
Time frame: first 30 days post-transplant
Serum Creatinine at Month 1, Month 6 and Month 12
Serum creatinine (SrCr) was measured at Month 1, Month 6 and Month 12.
Time frame: at Month 1, Month 6 and Month 12
Calculated Serum Creatinine Clearance at Month 1, Month 6 and Month 12
Creatinine clearance (CrCl) is the volume of blood plasma cleared of creatinine per unit time. It is a rapid and cost-effective method for the measurement of renal function.
Time frame: at Month 1, Month 6 and Month 12
Acute Rejection Episodes at Month 6 and Between Month 6 and Month 12
Acute rejection defined as an increase in serum creatinine level after exclusion of other causes of graft dysfunction, accompanied by a sudden decline in glomerular filtration rate and renal function and well-established diagnostic features on kidney allograft biopsy which can be either antibody-mediated and/or T cell-mediated and can occur at any time after transplant.
Time frame: at Month 6 and between Month 6 and Month 12
Patient Survival Rate
Numbers of patients alive, dead, and lost to follow up are reported.
Time frame: at Month 1, Month 6 and Month 12
Graft Survival Rate
Graft failure was defined as the failure of graft function for any reason, ultimately requiring renal replacement therapy and/or retransplantation (United States Renal Data System \[USRDS\] 2017.
Time frame: at Month 1, Month 6 and Month 12
74 pt. (25 \& 23 in reparixin continuous and intermittent infusion, and 26 in the pooled placebo) received the drug and were included in the safety population; 73 pt. (24, 23, 26) received both the study drug and the transplant and were included in the ITT. 1 started study drug but did not receive a kidney transplant, so was excluded from the ITT.
| Milestone | Reparixin Continuous Infusion | Reparixin Intermittent Infusion | Placebo Continuous/Intermittent Infusion |
|---|---|---|---|
| Started | 25 | 23 | 26 |
| Completed | 22 | 22 | 22 |
| Not completed | 3 | 1 | 4 |
| Withdrew: Transplantectomy | 2 | 1 | 3 |
| Withdrew: Transplant cancelled post treat start | 1 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 1 |
CrCl was determined by two 60 minute urine collections, during the time intervals 1-3 and 10-12 hours of allograft reperfusion. Blood was withdrawn at the midpoint of each urine collection. CrCl at each timepoint was calculated according to the formula: creatinine clearance (mL/minutes) = urine creatinine (mmol/L) x urine volume (mL) / serum creatinine (mmol/L) x time of collection (minutes) An average was to be calculated from the two 60 minute values in each interval.
| mL/min | Reparixin Continuous Infusion | Reparixin Intermittent Infusion | Placebo Continuous/Intermittent Infusion |
|---|---|---|---|
| 1-3 hours post-transplant | 5.11 ± 8.56 | 7.44 ± 12.81 | 6.30 ± 6.26 |
| 10-12 hours post-transplant | 9.66 ± 10.52 | 14.45 ± 17.39 | 10.75 ± 10.93 |
Serum creatinine (SrCr) was measured daily from Day 1 up to 7 days post-transplant or up to hospital discharge, whichever occurred earlier; in patients undergoing dialysis, SrCr values were measured immediately before dialysis.
| mmol/L | Reparixin Continuous Infusion | Reparixin Intermittent Infusion | Placebo Infusion |
|---|---|---|---|
| Day 1 | 0.686 ± 0.178 | 0.643 ± 0.219 | 0.651 ± 0.202 |
| Day 2 | 0.683 ± 0.244 | 0.576 ± 0.254 | 0.658 ± 0.278 |
| 0.Day 3 | 0.632 ± 0.311 | 0.500 ± 0.270 | 0.613 ± 0.317 |
| Day 4 | 0.589 ± 0.330 | 0.427 ± 0.260 | 0.601 ± 0.360 |
| Day 5 | 0.509 ± 0.281 | 0.383 ± 0.253 | 0.567 ± 0.367 |
| Day 6 | 0.510 ± 0.334 | 0.333 ± 0.206 | 0.570 ± 0.407 |
| Day 7 | 0.474 ± 0.351 | 0.318 ± 0.212 | 0.542 ± 0.411 |
Calculated glomerular filtration rate (GFR) was measured daily from Day 1 up to 7 days post-transplant or up to hospital discharge, whichever occurred earlier; in patients undergoing dialysis, SrCr values were measured immediately before dialysis
| mL/min | Reparixin Continuous Infusion | Reparixin Intermittent Infusion | Placebo Continuous/Intermittent Infusion |
|---|---|---|---|
| Day 1 | 6.04 ± 2.99 | 8.03 ± 6.46 | 7.03 ± 3.48 |
| Day 2 | 6.95 ± 5.00 | 10.68 ± 8.61 | 8.74 ± 8.06 |
| Day 3 | 10.99 ± 12.26 | 14.86 ± 11.67 | 13.15 ± 15.22 |
| Day 4 | 13.90 ± 15.15 | 19.64 ± 15.28 | 15.79 ± 18.57 |
| Day 5 | 17.97 ± 22.53 | 23.91 ± 19.02 | 18.61 ± 22.03 |
| Day 6 | 20.46 ± 24.24 | 26.64 ± 19.81 | 20.75 ± 24.01 |
| Day 7 | 22.42 ± 22.35 | 28.06 ± 20.10 | 22.70 ± 24.45 |
Urine output, measured in the interval from transplant to 8:00 of Day 1, and then daily from Day 2 up to 7 days post-transplant or up to hospital discharge, whichever occurred earlier
| mL | Reparixin Continuous Infusion | Reparixin Intermittent Infusion | Placebo Continuous/Intermittent Infusion |
|---|---|---|---|
| Day 1 | 1615.9 ± 2082.7 | 1749.9 ± 2109.9 | 1925.3 ± 2214.1 |
| Day 2 | 2242.7 ± 2236.8 | 2620.2 ± 2444.1 | 2844.5 ± 2861.2 |
| Day 3 | 2321.1 ± 2087.8 | 2979.6 ± 2000.1 | 2904.0 ± 2468.3 |
| Day 4 | 2409.8 ± 2043.2 | 2583.3 ± 1698.6 | 2939.4 ± 2585.0 |
| Day 5 | 1958.2 ± 1609.2 | 2474.8 ± 1575.4 | 2035.4 ± 1816.7 |
| Day 6 | 1795.8 ± 1206.2 | 2239.3 ± 1228.1 | 1994.8 ± 1688.5 |
| Day 7 | 2072.3 ± 1240.9 | 2226.1 ± 1093.2 | 1805.1 ± 1390.9 |
The number of patients who required dialysis within 7 days post-transplant was evaluated.
| Participants | Reparixin Continuous Infusion | Reparixin Intermittent Infusion | Placebo Infusion |
|---|---|---|---|
| Yes | 7 | 7 | 6 |
| No | 15 | 15 | 18 |
| Unknown | 2 | 1 | 2 |
the number of days on dialysis before resuming kidney function was evaluated.
| days | Reparixin Continuous Infusion | Reparixin Intermittent Infusion | Placebo Continuous/Intermittent Infusion |
|---|---|---|---|
| Number of Days on Dialysis Before Resuming Kidney Function | 2.5 ± 0.7 | 1.0 ± 0.0 | 2.0 ± 0.0 |
The number of patients who required dialysis within 7 days post-transplant was evaluated. Immediate graft function: SrCr ≤3 mg/dL on post operative day 5) Slow graft function: SrCr \>3 mg/dL dL on post operative day 5, no need of dialysis) Delayed graft function: Dialysis needed in the first week)
| Participants | Reparixin Continuous Infusion | Reparixin Intermittent Infusion | Placebo Continuous/Intermittent Infusion |
|---|---|---|---|
| Immediate graft function | 6 | 10 | 7 |
| Slow graft function | 8 | 5 | 11 |
| Delayed graft function | 8 | 8 | 6 |
| Unknown | 2 | 0 | 2 |
The mean duration of hospital stay was evaluated.
| days | Reparixin Continuous Infusion | Reparixin Intermittent Infusion | Placebo Continuous/Intermittent Infusion |
|---|---|---|---|
| Duration of Hospital Stay | 14.6 ± 8.4 | 16.1 ± 7.6 | 13.3 ± 7.9 |
Mortality in the first 30 days post-transplant was evaluated.
| Participants | Reparixin Continuous Infusion | Reparixin Intermittent Infusion | Placebo Continuous/Intermittent Infusion |
|---|---|---|---|
| No | 24 | 23 | 25 |
| Yes | 0 | 0 | 1 |
Serum creatinine (SrCr) was measured at Month 1, Month 6 and Month 12.
| mmo/L | Reparixin Continuous Infusion | Reparixin Intermittent Infusion | Placebo Continuous/Intermittent Infusion |
|---|---|---|---|
| Month 1 | 0.252 ± 0.2250 | 0.169 ± 0.0777 | 0.186 ± 0.0890 |
| Month 6 | 0.145 ± 0.0658 | 0.139 ± 0.0417 | 0.179 ± 0.1227 |
| Month 12 | 0.150 ± 0.0879 | 0.150 ± 0.0618 | 0.227 ± 0.2578 |
Creatinine clearance (CrCl) is the volume of blood plasma cleared of creatinine per unit time. It is a rapid and cost-effective method for the measurement of renal function.
| mL/min | Reparixin Continuous Infusion | Reparixin Intermittent Infusion | Placebo Continuous/Intermittent Infusion |
|---|---|---|---|
| Month 1 | 42.86 ± 22.56 | 44.75 ± 16.20 | 41.21 ± 14.23 |
| Month 6 | 52.43 ± 18.18 | 51.14 ± 12.54 | 46.93 ± 16.65 |
| Month 12 | 53.48 ± 20.39 | 51.10 ± 15.07 | 41.74 ± 19.03 |
Acute rejection defined as an increase in serum creatinine level after exclusion of other causes of graft dysfunction, accompanied by a sudden decline in glomerular filtration rate and renal function and well-established diagnostic features on kidney allograft biopsy which can be either antibody-mediated and/or T cell-mediated and can occur at any time after transplant.
| episodes | Reparixin Continuous Infusion | Reparixin Intermittent Infusion | Placebo Continuous/Intermittent Infusion |
|---|---|---|---|
| Month 6 | 2 | 6 | 2 |
| Between Month 6 and Month 12 | 0 | 0 | 4 |
Numbers of patients alive, dead, and lost to follow up are reported.
| Participants | Reparixin Continuous Infusion | Reparixin Intermittent Infusion | Placebo Continuous/Intermittent Infusion |
|---|---|---|---|
| Month 1 - Alive | 22 | 22 | 22 |
| Month 1 - Dead | 0 | 0 | 1 |
| Month 1 - Lost to follow up | 2 | 1 | 3 |
| Month 6 - Alive | 20 | 22 | 21 |
| Month 6 - Dead | 0 | 0 | 0 |
| Month 6 - Lost to follow up | 2 | 0 | 1 |
| Month 12 - Alive | 19 | 21 | 21 |
| Month 12 - Dead | 0 | 1 | 0 |
| Month 12 - Lost to follow up | 1 | 0 | 0 |
Graft failure was defined as the failure of graft function for any reason, ultimately requiring renal replacement therapy and/or retransplantation (United States Renal Data System \[USRDS\] 2017.
| number of grafts | Reparixin Continuous Infusion | Reparixin Intermittent Infusion | Placebo Continuous/Intermittent Infusion |
|---|---|---|---|
| Month 1 - Graft functioning | 21 | 22 | 22 |
| Month 1 - Graft failed | 3 | 1 | 3 |
| Month 6 - Graft functioning | 19 | 22 | 20 |
| Month 6 - Graft failed | 0 | 0 | 1 |
| Month 12 - Graft functioning | 18 | 20 | 20 |
| Month 12 - Graft failed | 1 | 1 | 0 |
Collected over All AEs were reported up to 10 days or hospital discharge. Thereafter, only untoward events that the Investigator assessed as at least possibly related to the study drug were recorded. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Reparixin Continuous Infusion | 0/25 (0%) | 12/25 (48%) | 24/25 (96%) |
| Reparixin Intermittent Infusion | 0/23 (0%) | 5/23 (21.7%) | 23/23 (100%) |
| Placebo Continuous/Intermittent Infusion | 1/26 (3.8%) | 9/26 (34.6%) | 25/26 (96.2%) |
| Event | Reparixin Continuous Infusion | Reparixin Intermittent Infusion | Placebo Continuous/Intermittent Infusion |
|---|---|---|---|
| RENAL VEIN THROMBOSISRenal and urinary disorders | 1/25 | 0/23 | 3/26 |
| METABOLIC ACIDOSISMetabolism and nutrition disorders | 2/25 | 0/23 | 0/26 |
| RENAL TUBULAR NECROSISRenal and urinary disorders | 2/25 | 0/23 | 1/26 |
| HYPOTENSIONVascular disorders | 2/25 | 0/23 | 0/26 |
| RETROPERITONEAL HAEMORRHAGEVascular disorders | 2/25 | 0/23 | 0/26 |
| IleusGastrointestinal disorders | 0/25 | 1/23 | 0/26 |
| KIDNEY TRANSPLANT REJECTIONImmune system disorders | 0/25 | 1/23 | 1/26 |
| URINARY ANASTOMOTIC LEAKInjury, poisoning and procedural complications | 0/25 | 1/23 | 0/26 |
| URETERIC FISTULARenal and urinary disorders | 1/25 | 1/23 | 1/26 |
| URETERAL NECROSISRenal and urinary disorders | 0/25 | 1/23 | 0/26 |
| Event | Reparixin Continuous Infusion | Reparixin Intermittent Infusion | Placebo Continuous/Intermittent Infusion |
|---|---|---|---|
| ANAEMIABlood and lymphatic system disorders | 6/25 | 10/23 | 12/26 |
| CONSTIPATIONGastrointestinal disorders | 8/25 | 5/23 | 6/26 |
| RENAL TUBULAR NECROSISRenal and urinary disorders | 5/25 | 7/23 | 7/26 |
| HYPOKALAEMIAMetabolism and nutrition disorders | 4/25 | 6/23 | 3/26 |
| DIABETES MELLITUSMetabolism and nutrition disorders | 6/25 | 3/23 | 4/26 |
| HYPOTENSIONVascular disorders | 6/25 | 5/23 | 3/26 |
| URINARY TRACT INFECTIONInfections and infestations | 4/25 | 5/23 | 2/26 |
| VOMITINGGastrointestinal disorders | 5/25 | 1/23 | 4/26 |
| ACIDOSISMetabolism and nutrition disorders | 4/25 | 2/23 | 5/26 |
| BLADDER SPASMRenal and urinary disorders | 4/25 | 2/23 | 1/26 |
| Age, Categorical(Participants) | Reparixin Continuous Infusion | Reparixin Intermittent Infusion | Placebo Continuous/Intermittent Infusion | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 25 | 23 | 26 | 74 |
| >=65 years | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | Reparixin Continuous Infusion | Reparixin Intermittent Infusion | Placebo Continuous/Intermittent Infusion | Total |
|---|---|---|---|---|
| Mean | 54.4 ± 7.4 | 55.9 ± 6.3 | 51.4 ± 11.3 | 53.8 ± 8.8 |
| Sex: Female, Male(Participants) | Reparixin Continuous Infusion | Reparixin Intermittent Infusion | Placebo Continuous/Intermittent Infusion | Total |
|---|---|---|---|---|
| Female | 18 | 13 | 19 | 50 |
| Male | 7 | 10 | 7 | 24 |
| Region of Enrollment(participants) | Reparixin Continuous Infusion | Reparixin Intermittent Infusion | Placebo Continuous/Intermittent Infusion | Total |
|---|---|---|---|---|
| France | 10 | 9 | 10 | 29 |
| United States | 2 | 2 | 4 | 8 |
| Spain | 7 | 5 | 4 | 16 |
| Italy | 6 | 7 | 8 | 21 |
Ran from Oct 2005 to primary completion in May 2008, 31 months.
Results were first posted in Apr 2020, 11 years 11 months after primary completion.
Of 18 phase 2 interventional studies under Reperfusion Injury, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 45. This study's 31 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Reparixin